Literature DB >> 21723969

Research strategies to improve snakebite treatment: challenges and progress.

Robert A Harrison1, Darren A Cook, Camila Renjifo, Nicholas R Casewell, Rachel B Currier, Simon C Wagstaff.   

Abstract

Antivenom is an effective treatment of snakebite but, because of the complex interplay of fiscal, epidemiological, therapeutic efficacy and safety issues, the mortality of snakebite remains unacceptably high. Efficiently combating this high level of preventable death amongst the world's most disadvantaged communities requires the globally-coordinated action of multiple intervention programmes. This is the overall objective of the Global Snakebite Initiative. This paper describes the challenges facing the research community to develop snakebite treatments that are more efficacious, safe and affordable than current therapy.
Copyright © 2011 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21723969     DOI: 10.1016/j.jprot.2011.06.019

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  25 in total

Review 1.  Distinct antibody species: structural differences creating therapeutic opportunities.

Authors:  Serge Muyldermans; Vaughn V Smider
Journal:  Curr Opin Immunol       Date:  2016-02-27       Impact factor: 7.486

2.  Adaptive evolution of distinct prey-specific toxin genes in rear-fanged snake venom.

Authors:  Cassandra M Modahl; Seth Frietze; Stephen P Mackessy
Journal:  Proc Biol Sci       Date:  2018-08-01       Impact factor: 5.349

3.  The structure of MP-4 from Mucuna pruriens at 2.22 Å resolution.

Authors:  Abha Jain; Amit Kumar; Meha Shikhi; Ashish Kumar; Deepak T Nair; Dinakar M Salunke
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-02-03       Impact factor: 1.056

4.  Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition.

Authors:  Stefanie K Menzies; Charlotte A Dawson; Edouard Crittenden; Rebecca J Edge; Steven R Hall; Jaffer Alsolaiss; Mark C Wilkinson; Nicholas R Casewell; Robert A Harrison; Stuart Ainsworth
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

Review 5.  Omics meets biology: application to the design and preclinical assessment of antivenoms.

Authors:  Juan J Calvete; Libia Sanz; Davinia Pla; Bruno Lomonte; José María Gutiérrez
Journal:  Toxins (Basel)       Date:  2014-12-15       Impact factor: 4.546

Review 6.  Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Authors:  Larissa M Alvarenga; Muhammad Zahid; Anne di Tommaso; Matthieu O Juste; Nicolas Aubrey; Philippe Billiald; Julien Muzard
Journal:  Toxins (Basel)       Date:  2014-08-21       Impact factor: 4.546

7.  Effective equine immunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis.

Authors:  Sompong Sapsutthipas; Poh Kuan Leong; Surasak Akesowan; Ronachai Pratanaphon; Nget Hong Tan; Kavi Ratanabanangkoon
Journal:  PLoS Negl Trop Dis       Date:  2015-03-16

8.  VTBuilder: a tool for the assembly of multi isoform transcriptomes.

Authors:  John Archer; Gareth Whiteley; Nicholas R Casewell; Robert A Harrison; Simon C Wagstaff
Journal:  BMC Bioinformatics       Date:  2014-12-03       Impact factor: 3.169

9.  Mass Drug Administration and beyond: how can we strengthen health systems to deliver complex interventions to eliminate neglected tropical diseases?

Authors:  Eleanor E Macpherson; Emily R Adams; Moses J Bockarie; T Deirdre Hollingsworth; Louise A Kelly-Hope; Mike Lehane; Vanja Kovacic; Robert A Harrison; Mark Ji Paine; Lisa J Reimer; Stephen J Torr
Journal:  BMC Proc       Date:  2015-12-18

10.  Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite.

Authors:  Robert A Harrison; José María Gutiérrez
Journal:  Toxins (Basel)       Date:  2016-11-24       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.